|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This behavior recommends that treatment of osteoporosis via calcitonin does not provide the required upshots.
|
31121190 |
2020 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Controlled Delivery of Salmon Calcitonin Using Thermosensitive Triblock Copolymer Depot for Treatment of Osteoporosis.
|
30729223 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calcitonin (elcatonin [eCT]) has been used mainly for hypercalcemia and pain associated with osteoporosis.
|
30655691 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, calcitonin injection has been used to treat osteoporosis and Paget's disease of bone. hCT is an aggregation-prone peptide with a high tendency to form amyloid fibrils.
|
31692350 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These biological agents include anti-osteoporosis drugs: net anabolics (parathyroid hormone/analogs, androgens, calcilytics, anti-sclerostin antibody), net anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter-2 inhibitors, insulin).
|
31079501 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, this issue was addressed by evaluating the effect of osteoporosis medications, such as the anabolic agent PTH [teriparatide (TPTD)] and the antiresorptive agents calcitonin [elcatonin (ECT)] and bisphosphonate [risedronate (RIS)], on bone metabolism as well as on glucose and lipid metabolism in spontaneously diabetic Torii (SDT) fatty rats, which are a model of type 2 DM (T2DM).
|
31504411 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacy data from VA's Corporate Data Warehouse were used to identify prescriptions for Food and Drug Administration-approved pharmacological treatments for osteoporosis including bisphosphonates, calcitonin, denosumab, raloxifene and teriparatide.<b>Outcome Measures:</b> Demographics, clinical and SCI-related characteristics, receipt of a dual energy x-ray absorptiometry (DXA), and prevalent lower extremity fractures were examined to determine factors related to receiving a pharmacological agent for osteoporosis.<b>Results:</b> 1,041 persons (9.4%) had a prescription for a pharmacological agent for osteoporosis; the majority (<i>n</i> = 964, 93.0%) were bisphosphonates.
|
30888309 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
|
31054990 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calcitonin has been in clinical use for conditions of accelerated bone turnover, including Paget's disease and osteoporosis; although in recent years, with the development of drugs that are more potent inhibitors of bone resorption, its use has declined.
|
30540227 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
One treatment of osteoporosis is elcatonin, a kind of calcitonin.
|
31041475 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies on changes in (calcitonin gene-related peptide) CGRP and bone metabolism and osteoporosis prevention after SCI have important clinical significance.
|
29462059 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although calcitonin is an effective drug used to treat osteoporosis in clinical practice, it also exists such problems as high cost, short half-life, and high immunogenicity.
|
29745315 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that calcitonin could alleviate lower back pain in patients with osteoporosis or neuropathic pain by the alteration in receptor or channel expression.
|
28726540 |
2018 |
|
Osteoporosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The level of H<sub>2</sub>S in the plasma was determined and common laboratory indicators to diagnose osteoporosis, such as alkaline phosphatase (ALP) activity and the levels of osteocalcin (OCN), calcitonin, parathyroid hormone and leptin were measured.
|
30305826 |
2018 |
|
Osteoporosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Basic and clinical advances in research over the past two decades have led to the development of different compounds with antiresorptive or anabolic activity on bone that improved substantially the management of patients with osteoporosis over calcitonin or estrogen replacement.
|
29869573 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified 9995 patients who were diagnosed with osteoporosis and prescribed osteoporosis drugs (bisphosphonate (n = 4675), calcitonin (n = 3993) and SERMs (n = 1327)) between 1 January 2000 and 31 December 2006 in Taiwan's National Health Insurance Research Database.
|
28981741 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We note a watershed in osteoporosis drug discovery around the year 2000, when the approach to developing novel therapeutics shifted from one driven by discoveries in animal studies and clinical observations (eg, oestrogen, calcitonin, and teriparatide) or opportunistic repurposing of existing compounds (eg, bisphosphonates) to one driven by advances in fundamental bone biology (eg, denosumab) coupled with clues from patients with rare bone diseases (eg, romosozumab, odanacatib).
|
28689769 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the therapeutic effect of gelatin microspheres containing different concentrations of calcitonin gene-related peptide (CGRP) or substance P on repairing bone defects in a rabbit osteoporosis model.
|
27909823 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calcitonin (CT) is an anti-absorbent, which has long been used for treatment of osteoporosis.
|
28514714 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the first antiresorptive substances used in the prevention and treatment of osteoporosis is calcitonin (CT), a hypocalcemic hormone that potently inhibits osteoclastic bone resorption.
|
28220476 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, patients were required to have an osteoporosis medication prescription for a bisphosphonate (alendronate, risedronate, pamidronate, etidronate, zoledronate, and tiludronate), calcitonin, denosumab, raloxifene, or teriparatide during the follow-up period.
|
29083977 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the peptide hormone calcitonin in skeletal protection has led to its use as a therapeutic for osteoporosis.
|
28739873 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calcitonin and strontium ranelate are also not included, because their indication for osteoporosis has recently been limited or withdrawn.
|
28131131 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calcitonin (CT) plays a role in the pathogenesis of osteoporosis and genetic variations in or adjacent to the CT gene may be associated with loss of bone mineral density (BMD).
|
17026622 |
2006 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A series of xanthine sulfonamides is presented as a class of calcitonin (CT) inducers - a potentially new method for treating diseases associated with postmenopausal bone loss such as osteoporosis.
|
10737755 |
2000 |